Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-16-013610
Filing Date
2016-02-17
Accepted
2016-02-17 18:47:20
Documents
1
Period of Report
2016-02-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 12333
  Complete submission text file 0000899243-16-013610.txt   14591
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-37695 | Film No.: 161435550
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-37695 | Film No.: 161435551

Mailing Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 617-225-0096
PROTEOSTASIS THERAPEUTICS, INC. (Issuer) CIK: 0001445283 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
SIC: 2834 Pharmaceutical Preparations